Here are just a few editorial highlights from the DDNews Cancer Research News site and other online vehicles of DDNews magazine to get you acquainted with the website and show you the range of our coverage.

By Dr. Dragan Cicic, Actinium Pharmaceuticals Inc.
Patients with blood cancers often face poor long-term survival outcomes, but a new treatment approach could offer more effective targeting of cancer cells as well as lower toxicity.
By Kelsey Kaustinen, DDNews Senior Editor
If all milestones are met, the agreement could be worth up to $817 million
By Kelsey Kaustinen, DDNews Senior Editor
The effectiveness of anthracyclines, a standard of cancer care, is marred by the associated heart damage they cause; a recent study, however, reports that wrapping the drugs in a fatty cover can minimize cardiotoxicity.
By Lloyd Dunlap, DDNews Managing Editor
Immunomedics Inc. has received notice from the U.S. Food and Drug Administration designating as a Fast Track development program the investigation of sacituzumab govitecan, the company's lead antibody-drug conjugate, for the treatment of patients with triple-negative breast cancer
By Kelsey Kaustinen, DDNews Senior Editor
When the STP axis is expressed, causing low REST protein levels, clinical outcomes in the lab are poor, while inhibition of the axis was found to increase REST levels, which impaired tumor formation and progression.

Horizon Diagnostics, UK NEQAS announce strategic partnership
March 2012

CAMBRIDGE, U.K.—Horizon Diagnostics, a division of Horizon Discovery, and the United Kingdom National External Quality Assessment Service (UK NEQAS ICC) have announced a strategic partnership agreement for the development of genetically defined reference standards for novel lung cancer biomarkers. With the new standards, variability can be minimized in FISH- and IHC-based diagnostic testing when it comes to prescription of therapies. Per the agreement, UK NEQAS ICC will receive an exclusive license to distribute reference standards pertaining to certain lung cancer biomarkers in the U.K. and elsewhere in Europe for proficiency testing in its quality assessment program.  
"We look forward to seeing our genetically defined reference standards adopted in proficiency schemes and as batch controls, ultimately helping to improve the accuracy of diagnostic testing for patients," said Dr. Paul Morrill, commercial director for Horizon Discovery, in a statement.

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2015 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.